Cargando…

Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study

BACKGROUND: Infliximab (IFX) effectively treats patients with inflammatory bowel disease (IBD). IFX-biosimilar (IFX-BS) has the same amino acid sequence as that of the IFX originator, and its increasing use is expected to reduce national healthcare costs. Long-term efficacy and safety of IFX-BS in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazama, Tomoe, Ando, Katsuyoshi, Ueno, Nobuhiro, Fujiya, Mikihiro, Ito, Takahiro, Maemoto, Atsuo, Ishigami, Keisuke, Nojima, Masanori, Nakase, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497130/ https://www.ncbi.nlm.nih.gov/pubmed/37699041 http://dx.doi.org/10.1371/journal.pone.0288393

Ejemplares similares

Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
por: Kashima, Shin, et al.
Publicado: (2021)

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
por: Ito, Takahiro, et al.
Publicado: (2020)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Pilot study of endoscopic retrograde 3-dimensional – computed tomography enteroclysis for the assessment of Crohn’s disease
por: Tanabe, Hiroki, et al.
Publicado: (2017)

Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease
por: Sakatani, Aki, et al.
Publicado: (2013)

The efficacy of the submucosal injection of lidocaine during endoscopic submucosal dissection for colorectal neoplasms: a multicenter randomized controlled study
por: Ijiri, Masami, et al.
Publicado: (2020)

Successful medical treatment for a Crohn’s disease patient with a perforation by a second-generation patency capsule
por: Tanabe, Hiroki, et al.
Publicado: (2018)

Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia
por: Iwama, Takuya, et al.
Publicado: (2016)

The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
por: Yamawaka, Tsukasa, et al.
Publicado: (2022)

Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
por: Yamakawa, Tsukasa, et al.
Publicado: (2023)

Endoscopic recanalization for the complete closure of long-gap esophageal atresia after reconstruction surgery
por: Kashima, Shin, et al.
Publicado: (2022)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Probiotic-Derived Polyphosphate Accelerates Intestinal Epithelia Wound Healing through Inducing Platelet-Derived Mediators
por: Isozaki, Shotaro, et al.
Publicado: (2021)

The Identification of RNA-Binding Proteins Functionally Associated with Tumor Progression in Gastrointestinal Cancer
por: Konishi, Hiroaki, et al.
Publicado: (2021)

Testis‐specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilization
por: Murakami, Yuki, et al.
Publicado: (2022)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2018)

A Case of Alpha-Fetoprotein-Producing Adenocarcinoma of the Esophagogastric Junction in which Long-Term Survival Was Achieved by Means of Individualized Multidisciplinary Therapy
por: Tanaka, Kazuyuki, et al.
Publicado: (2018)

A tumor-specific modulation of heterogeneous ribonucleoprotein A0 promotes excessive mitosis and growth in colorectal cancer cells
por: Konishi, Hiroaki, et al.
Publicado: (2020)

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2022)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Heterogenous Nuclear Ribonucleoprotein H1 Promotes Colorectal Cancer Progression through the Stabilization of mRNA of Sphingosine-1-Phosphate Lyase 1
por: Takahashi, Keitaro, et al.
Publicado: (2020)

Bacteria‐derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis‐associated cancer
por: Iwama, Takuya, et al.
Publicado: (2021)

Carbazochrome sodium sulfonate is not effective for prevention of post-gastric endoscopic submucosal dissection bleeding: A retrospective study
por: Takahashi, Keitaro, et al.
Publicado: (2022)

The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
por: Sugiyama, Yuya, et al.
Publicado: (2023)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Probiotic Aspergillus oryzae produces anti-tumor mediator and exerts anti-tumor effects in pancreatic cancer through the p38 MAPK signaling pathway
por: Konishi, Hiroaki, et al.
Publicado: (2021)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Endoscopic findings of gastric mixed adenoneuroendocrine carcinoma: A case report
por: Takahashi, Keitaro, et al.
Publicado: (2020)

Gastric submucosa-invasive carcinoma associated with Epstein-Barr virus and endoscopic submucosal dissection: A case report
por: Kobayashi, Yu, et al.
Publicado: (2019)

Correlation Among Body Composition Parameters and Long-Term Outcomes in Crohn's Disease After Anti-TNF Therapy
por: Ando, Katsuyoshi, et al.
Publicado: (2022)

Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease
por: Ichimiya, Tadashi, et al.
Publicado: (2023)

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
por: Matsumoto, Tsugumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9moid1gfk742pdebi2fr7qd525